EDAP TMS announced the execution of a letter of intent for a EUR 36 million credit facility with the European Investment Bank (EIB). This financing is intended to support the continued expansion of the Focal One Robotic HIFU platform in focal therapy.
The proceeds from this low-interest funding will also accelerate the development of new clinical indications for EDAP's technology. The credit facility is expected to close no later than the end of calendar year 2025, pending the signature of final legal documents.
This agreement immediately enhances EDAP's balance sheet, providing a substantial source of capital that can be accessed in tranches as needed. The funding is crucial for advancing the company's growth initiatives and expanding patient access to Focal One Robotic HIFU.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.